161P Population effectiveness model of the consequences of recurrence after trastuzumab emtansine (T-DM1) treatment among U.S. patients with high-risk HER2+ early-stage breast cancer (ESBC)
| Autor: | Veenstra, D.L., Hendrix, N., Dolan, C.M., Fisher, K.A., Lalla, D., Oestreicher, N., Moy, B. |
|---|---|
| Zdroj: | In Annals of Oncology September 2021 32 Supplement 5:S430-S431 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|